CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
OXFORD, United Kingdom, April 06, 2016 -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn Edwards, Chief Executive Officer, will present at Needham & Company’s 15th Annual Healthcare Conference, 13 April 2016 at 11:20am EDT in New York City.
A live audio webcast of the presentation will be available through the Investors section on the Company’s website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit | |
| Glyn Edwards / Richard Pye (UK office) | Tel: +44 (0)1235 443 951 |
| Erik Ostrowski / Michelle Avery (US office) | +1 617 225 4455 |
| Cairn Financial Advisers LLP | |
| (Nominated Adviser) | |
| Liam Murray / Tony Rawlinson | Tel: +44 (0)20 77148 7900 |
| N+1 Singer | |
| (Broker) | |
| Aubrey Powell / Jen Boorer | Tel: +44 (0)20 7496 3000 |
| Peckwater PR | |
| (Financial public relations, UK) | Tel: +44 (0)7879 458 364 |
| Tarquin Edwards | [email protected] |
| MacDougall Biomedical Communications | |
| (US media contact) | Tel: +1 781 235 3060 |
| Chris Erdman | [email protected] |
-END-
